ACADIA Pharmaceuticals (ACAD) vs Enliven Therapeutics (ELVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Enliven Therapeutics (ELVN) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 100.0% versus a loss of 8.1%. Over five years, ELVN leads with a +177.5% price change compared with +11.8% for ACAD. ACADIA Pharmaceuticals is the larger company by market cap ($3.37 billion vs $2.98 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | ELVN |
|---|---|---|
| Share price | $19.58 | $40.63 |
| Market cap | $3.37B | $2.98B |
| 1-day change | -0.36% | -1.76% |
| YTD return | -26.69% | +163.83% |
| 1-year return | -8.12% | +99.95% |
| 5-year return | +11.82% | +177.53% |
| P/E ratio (TTM) | 8.82 | — |
| Forward P/E | 22.04 | — |
| EPS (TTM) | $2.22 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.07B | — |
| Revenue growth (YoY) | +11.87% | — |
| Net income (latest FY) | $391.00M | $-103.69M |
| Gross margin | 91.69% | — |
| Operating margin | 9.78% | — |
| Net margin | 36.49% | — |
| 52-week high | $30.96 | $62.32 |
| 52-week low | $19.32 | $14.79 |
| Distance from 52-week high | -36.76% | -34.80% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +64.25% | +81.32% |
| Average volume | 1.85M | 1.12M |
| Shares outstanding | 172.31M | 73.27M |
| Employees | 796 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELVN has outperformed ACAD by 108.1 percentage points over the past year.
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
ACAD vs ELVN FAQ
Which is bigger, ACADIA Pharmaceuticals or Enliven Therapeutics?
ACADIA Pharmaceuticals (ACAD) is larger, with a market capitalization of $3.37B compared with $2.98B for Enliven Therapeutics (ELVN).
Which stock has performed better over the past year, ACAD or ELVN?
ELVN returned +99.95% over the past 12 months, compared with -8.12% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and Enliven Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.